Concordia Healthcare Corp. / Amdipharm Mercury Limited (AMCo)

Off-Patent Specialty Pharmaceuticals (Multi-TA)

Disease Overview

AMCo's portfolio spans 190+ off-patent branded specialty molecules across endocrinology (e.g., liothyronine), ophthalmology, urology, GI, and CNS — drugs that have lost patent protection but retain pricing power in fragmented international markets. The thesis depends on niche category control, formulary inertia, and regulatory complexity that limit generic entry. In the UK, this category drew sustained CMA scrutiny; Concordia's liothyronine pricing became a 2017-2020 antitrust case.

Competitive Landscape

The 2015 off-patent specialty roll-up landscape was crowded with debt-fueled buyers chasing the same playbook: Valeant (post-Salix, mid-meltdown), Endo (Auxilium, Par Pharmaceutical), Mallinckrodt (Questcor/Acthar), Horizon, and Concordia itself (post-Donnatal, post-Covis). AMCo brought 190+ molecules and 100+ country reach from Cinven's Amdipharm + Mercury combination, positioning Concordia as a transatlantic specialty platform with US (Concordia North America), UK (AMCo), and EM exposure. The deal was financed with ~$2.8B of high-yield debt (max blended ~7.25%), $520M equity, 8.49M Concordia shares to Cinven, and up to $220M earn-out — a leverage ratio that became untenable when (a) the Valeant-led collapse of the off-patent specialty pricing model began in late 2015, (b) the UK CMA opened a Statement of Objections on liothyronine pricing, and (c) generic entry hit Donnatal and Plaquenil. By October 2017 Concordia was in CBCA proceedings; the company rebranded to Advanz Pharma in November 2018 after restructuring, with Cinven returning as a major equity holder. The AMCo deal is now a case study in late-cycle specialty roll-up overpayment.